There is an increasing awareness of the importance of the gut microbiome in the health and wellbeing of us all. Current Next Generation Sequencing (NGS) technologies have contributed greatly to our understanding of the microbiome. However, they lack the speed, reproducibility and (for 16S amplicon sequencing) the level of detail necessary to provide useful and actionable information in a clinical setting.
Bio-Me has developed a highly accurate, detailed and high-throughout microbiome analysis platform, based on targeting the most relevant species of bacteria.
Bio-Me’s Precision Microbiome Profiling (PMP) is a novel approach to microbiome analysis that utilizes targeted quantitative PCR instead of traditional DNA sequencing. It provides distinct benefits with the accuracy and reproducibility of bacterial species quantification.
By collaborating with Thermo Fisher Scientific, we have utilized their long expertise in TaqMan PCR on their OpenArray platform. This results in a rapid and highly reproducible assay of 50 – 200 different target bacteria from hundreds of samples per day.
Precision Microbiome Profiling – PMP™ – has been developed to enable rapid, high-throughput microbiome analysis at species, sub-species and strain-level resolution. PMP™ is an attractive alternative to Next Generation Sequencing (NGS) technologies (both 16S rRNA amplicon sequencing and Whole Genome Sequencing). It can also be used to validate taxonomic abundance information obtained from NGS.
PMP™ is particularly useful for uniform analysis of many samples, as well as applications closer to clinical utility, like stratification of patients in clinical trials and companion diagnostics. Please feel free to contact Bio-Me if you have any questions about any of these applications of PMP™.